Navigation Links
Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
Date:6/3/2008

ecently as Assistant Professor of Medical Oncology at the Lombardi Cancer Center, Georgetown University Medical Center. She received her Ph.D. from the Department of Physiology at Johns Hopkins University School of Medicine, her M.D. from the Medical College of Pennsylvania and a B.A. from Boston University.

Dr. Fox joined Sunesis in 2006 as Senior Director, Program Leader and will now have an expanded role as Vice President, Product and Preclinical Development. Previously, she served as Senior Director in the Translational Sciences Department for Chiron Corporation (now Novartis AG) from 2005 to 2006, where she led the clinical pharmacology and preclinical pharmokinetics (PK)/drug metabolism group, supporting the development of the company's novel oncology compounds. From 2002 to 2005, Dr. Fox was Senior Director/Senior Staff Scientist for Genencor International, where she started the Pharmacological Sciences Department. Dr. Fox's industry career began in the PK/Metabolism Department for Genentech, where she ultimately led the group responsible for all oncology projects from late-stage research through clinical development. This was preceded by leadership of the immunology focus area within the PK/Metabolism Department. During her ten years at Genentech, she contributed to the development of products such as Herceptin(R), Xolair(R), Raptiva(R) and Avastin(R). Dr. Fox received her Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology and an A.B. in Chemistry from Bryn Mawr College. She conducted postdoctoral research at The Rockefeller University.

Dr. Michelson joined Sunesis in 2006 as Senior Director and Head of Clinical Science, Oncology, bringing more than a decade of experience as a medical oncologist and in drug development in both industry and academic settings. Newly promoted to the position of Vice President, Clinical Strategy, he will oversee the clinical development of Sunesis' novel cancer therapeutics, with an emphas
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... US-Australian drug discovery company, Novogen Ltd, (ASX:NRT; NASDAQ: ... University, on March 27 released pre-clinical data on experimental ... oral presentation by Professor Gil Mor MD ... Annual Scientific Meeting of the Society of Reproductive ... In both in vitro and in animal ...
(Date:3/30/2015)... , March 30, 2015  Spherix Incorporated (Nasdaq: ... to the fostering and monetization of intellectual property, ...  Case No. 3:13-cv-03494-M and  Spherix v. Uniden , ... District Court for the Northern District of ... Spherix v. Verizon, Case No. 1:14-cv-00721-GBL-TCB, ...
(Date:3/30/2015)... , March 30, 2015 ... Richmond Pharmacology ist das erste Zentrum ... am Royal Free Hospital in London ... Untersuchung eines RNAi-Therapeutikums Studienversuche an einem Patienten begonnen ... Transthyretin vermittelter Amyloidose entwickelt (ATTR), einer seltenen Herz- ...
(Date:3/29/2015)... 2015 Caris Life Sciences® today ... showing the presence of PD-1 and PD-L1 ... Using Caris Molecular Intelligence®, the company,s panomic ... of programmed cell death protein-1 (PD-1) in ... its ligand (PD-L1) expression was variable across ...
Breaking Biology Technology:Yale University and Novogen Release Data on Cantrixil Mode of Action 2Yale University and Novogen Release Data on Cantrixil Mode of Action 3Yale University and Novogen Release Data on Cantrixil Mode of Action 4Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 2Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4
... 2012  Discovery Laboratories, Inc. (NASDAQ: DSCO ) ... demonstrating that the lower rate of reintubation previously reported ... with infants treated with Curosurf ® and Survanta ... resulted in a potential hospital cost savings of $160,000 ...
... microscope in the hope of reducing the time taken to diagnose ... and 1 cm wide at its tip, could be used by ... guidance tool; dentists could also use it to screen for early-stage ... April, in IOP Publishing,s Journal of Micromechanics and Microengineering , ...
...   AMRI (NASDAQ: AMRI ) ... its research and contract manufacturing services on the ... industries. AMRI SMARTSOURCING™ is a series of strategic ... outcomes. SMARTSOURCING™ is based on 21 years of ...
Cached Biology Technology:Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated with Reintubation in Premature Infants 2Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated with Reintubation in Premature Infants 3Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated with Reintubation in Premature Infants 4Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated with Reintubation in Premature Infants 5Handheld probe shows great promise for oral cancer detection 2AMRI Launches SMARTSOURCING™ For Contract Manufacturing and Research Services 2
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs ... management company, today announced that the Company will demonstrate ... both enterprise and consumers at Connect:ID on March 23 ... HOYOS Labs will highlight the IEEE Biometric Open ... ; and enterprise access control system. BOPS was ...
(Date:3/20/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces its ... of the products featured in 2015 "I Want That" ... PM EST on the DIY Network.   ... Vegas , site of the 2015 International CES ...
(Date:3/17/2015)... , March 17, 2015 Emotient, the ... software, today announced general availability of Emotient ... for the analysis of facial expressions. The system ... media content, products and services. It delivers audience ... and sentiment - as derived from facial evidence ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... Innovation in New Zealand have developed a new chemical approach ... treat Alzheimer,s disease. The team used a ... heparan sulphates, which are known to control the formation of ... Heparan sulphates are found in nearly every cell of the ...
... in one of Western Europe,s largest lakes, Lake Geneva, in ... ocean have shown that these small bits of plastic can ... or other small waterborne organisms, the full extent of their ... The study, which is being extending under a mandate by ...
... 2013 /PRNewswire-iReach/ -- The National Association of Specialty ... joined the association as a Founding Corporate Member. ... the industry including specialty pharmacies, pharmaceuticals companies, health ... "We are honored and excited to ...
Cached Biology News:New chemical approach to treat Alzheimer's 2Microplastic pollution prevalent in lakes too 2Microplastic pollution prevalent in lakes too 3CARE Pharmacies Joins National Association of Specialty Pharmacy (NASP) as a Founding Corporate Member 2
... and biologic production demands on cell and ... viable cell populations. Therefore, both cell concentration ... determined accurately and precisely. The new Vi-CELLTM ... cost effective means to perform the trypan ...
... PowerPac Basic power supply are used for electrophoretic ... cell accommodates two 7.5 x 10 cm gels ... assembly, Bio-Ice cooling unit, buffer tank, lid with ... basic power supply, 100-120 and 220-240 V, provides ...
...
... clear polystyrene with frosted labeling surfaces, ... cell counting. 100% integrity tested. Linkage: ... product number, created to easily match ... availability yet, please order under the ...
Biology Products: